Raras
Buscar doenças, sintomas, genes...
Síndrome Myhre
ORPHA:2588CID-10 · Q87.8OMIM 139210DOENÇA RARA

A síndrome de Myhre é marcada por uma musculatura muito desenvolvida, baixa estatura, pouca mobilidade nas articulações, dedos curtos, perda auditiva mista e deficiência intelectual em graus variados. O rosto apresenta características como aberturas dos olhos pequenas (fendas palpebrais curtas), um sulco curto entre o nariz e o lábio superior (filtro labial), lábios finos, desenvolvimento insuficiente da parte superior da mandíbula (hipoplasia maxilar) e queixo projetado para frente (prognatismo). Pele mais grossa foi observada em seis pacientes.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A síndrome de Myhre é marcada por uma musculatura muito desenvolvida, baixa estatura, pouca mobilidade nas articulações, dedos curtos, perda auditiva mista e deficiência intelectual em graus variados. O rosto apresenta características como aberturas dos olhos pequenas (fendas palpebrais curtas), um sulco curto entre o nariz e o lábio superior (filtro labial), lábios finos, desenvolvimento insuficiente da parte superior da mandíbula (hipoplasia maxilar) e queixo projetado para frente (prognatismo). Pele mais grossa foi observada em seis pacientes.

Pesquisas ativas
1 ensaio
1 total registrados no ClinicalTrials.gov
Publicações científicas
106 artigos
Último publicado: 2026 Apr 13

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Antenatal
+ infancy, neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: Q87.8
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
26 sintomas
😀
Face
13 sintomas
🧠
Neurológico
10 sintomas
👁️
Olhos
7 sintomas
❤️
Coração
6 sintomas
📏
Crescimento
6 sintomas

+ 36 sintomas em outras categorias

Características mais comuns

100%prev.
Hiperlordose lombar
Obrigatório (100%)
100%prev.
Início na infância
Obrigatório (100%)
100%prev.
Lóbulo da orelha pequeno
Obrigatório (100%)
100%prev.
Sobrancelha muito arqueada
Obrigatório (100%)
100%prev.
Calvária espessada
Frequência: 18/18
100%prev.
Limitação da mobilidade articular
Frequência: 11/11
118sintomas
Muito frequente (40)
Frequente (19)
Ocasional (34)
Sem dados (25)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 118 características clínicas mais associadas, ordenadas por frequência.

Hiperlordose lombarLumbar hyperlordosis
Obrigatório (100%)100%
Início na infânciaChildhood onset
Obrigatório (100%)100%
Lóbulo da orelha pequenoSmall earlobe
Obrigatório (100%)100%
Sobrancelha muito arqueadaHighly arched eyebrow
Obrigatório (100%)100%
Calvária espessadaThickened calvaria
Frequência: 18/18100%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico106PubMed
Últimos 10 anos76publicações
Pico202517 papers
Linha do tempo
2026Hoje · 2026🧪 2010Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.

SMAD4SMAD family member 4Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response el

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
Transcriptional regulation of pluripotent stem cellsSMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionDownregulation of SMAD2/3:SMAD4 transcriptional activitySignaling by ActivinSignaling by NODAL
MECANISMO DE DOENÇA

Pancreatic cancer

A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
37.2 TPM
Ovário
34.9 TPM
Cervix Endocervix
34.5 TPM
Cérebro - Hemisfério cerebelar
32.5 TPM
Nervo tibial
32.3 TPM
OUTRAS DOENÇAS (7)
Myhre syndromejuvenile polyposis syndromejuvenile polyposis/hereditary hemorrhagic telangiectasia syndromefamilial pancreatic carcinoma
HGNC:6770UniProt:Q13485

Variantes genéticas (ClinVar)

1,957 variantes patogênicas registradas no ClinVar.

🧬 SMAD4: NM_005359.6(SMAD4):c.761C>T (p.Thr254Ile) ()
🧬 SMAD4: NM_005359.6(SMAD4):c.430T>A (p.Ser144Thr) ()
🧬 SMAD4: NM_005359.6(SMAD4):c.249+12_249+13del ()
🧬 SMAD4: NM_005359.6(SMAD4):c.788-9A>T ()
🧬 SMAD4: NM_005359.6(SMAD4):c.1640A>G (p.Asp547Gly) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 225 variantes classificadas pelo ClinVar.

79
146
Patogênica (35.1%)
VUS (64.9%)
VARIANTES MAIS SIGNIFICATIVAS
DUT-AS1: NC_000015.10:g.48310852_48310879dup [Pathogenic]
SMAD4: NM_005359.6(SMAD4):c.1060_1066delinsT (p.Val354_Pro356delinsSer) [Likely pathogenic]
SMAD4: NM_005359.6(SMAD4):c.1541del (p.Pro514fs) [Likely pathogenic]
SMAD4: R496C [Pathogenic]
SMAD4: NM_005359.6(SMAD4):c.875del (p.Pro292fs) [Pathogenic/Likely pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome Myhre

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
75 papers (10 anos)
#1

Identification and characterization of a TGF-β-independent SMAD4-NFATc1-STAT3 regulatory axis.

Journal of molecular cell biology2026 Jan 24

SMAD4, a central mediator of the TGF-β signaling pathway, plays a critical role in regulating cellular processes such as proliferation, differentiation, and apoptosis. While SMAD4's canonical functions within TGF-β signaling are well-established, its non-canonical, TGF-β-independent roles remain poorly understood, particularly in the context of disease biology. Here, we investigate SMAD4's TGF-β-independent functions by identifying and characterizing its protein-protein interaction network. Using pancreatic ductal adenocarcinoma as a model system, we performed a SMAD4-focused oncogenic protein-protein interaction mapping and uncovered a novel interaction between SMAD4 and NFATc1. We demonstrated that SMAD4 binds to NFATc1 in a phosphorylation-dependent but TGF-β-independent manner, sequestering NFATc1 in the cytoplasm and inhibiting its transcriptional activity. The absence of this interaction in SMAD4-deficient PDAC cells is associated with the activation of NFATc1 transcriptional programs and upregulation of STAT3 at both mRNA and protein levels. Pharmacological profiling revealed multiple STAT3 inhibitors with selective efficacy against SMAD4-deficient PDAC cells in vitro, highlighting a potential therapeutic vulnerability. These findings identify a previously uncharacterized SMAD4-NFATc1 regulatory complex and establish its biological significance in regulating NFATc1-driven transcriptional programs, such as STAT3, providing critical insights into SMAD4's TGF-β-independent functions and uncovering new opportunities for therapeutic intervention in SMAD4-deficient contexts.

#2

Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents.

American journal of medical genetics. Part C, Seminars in medical genetics2026 Mar 16

Myhre Syndrome (MYHRS, MIM #139210) is a rare, multisystem connective tissue disorder caused by recurrent heterozygous gain-of-function pathogenic variants in the SMAD4 gene, a key player in TGF-β signaling and a regulator of extracellular matrix homeostasis. MYHRS is characterized by a progressive fibrotic phenotype affecting multiple organ systems, including the skeletal, cardiovascular, respiratory, and integumentary systems. MYHRS individuals often present with short stature, joint contractures, cardiac valve defects, subglottic stenosis, and skin thickening. Neurodevelopmental disorders, including autism spectrum disorder, may also occur. Despite the recurrent mutations, MYHRS individuals have significant phenotypic variability. Treatment for MYHRS is symptomatic, and no disease-modifying therapies are currently available. In this article, we discuss potential future therapies in MYHRS, such as TGF-β inhibitors, anti-fibrotic drugs, and gene editing approaches. Furthermore, we discuss unmet needs on clinical and biochemical endpoints that are critical for the investigation of new therapies.

#3

Myhre Syndrome Presenting With Congenital Proximal Radioulnar Synostosis: A Case Report.

Cureus2026 Jan

Myhre syndrome (MS) is a rare, autosomal dominant multisystem disorder. Clinical features include short stature, variable degrees of intellectual disability, distinctive facial dysmorphism, musculoskeletal abnormalities, cardiopulmonary disorders, and abnormal sexual development. We report on an 11-year-old male Taiwanese patient who was initially referred to our genetic counseling clinic due to congenital proximal radioulnar synostosis (PRUS) and clinical suspicion of mucopolysaccharidosis. A pathogenic heterozygous missense variant in SMAD4, c.1498A>G (p.Ile500Val), was subsequently identified, confirming the diagnosis of MS. This case demonstrates the typical clinical phenotype along with the unique finding of PRUS, which has not been previously reported in association with this syndrome. This report highlights PRUS as a rare skeletal manifestation, expanding the known clinical spectrum of MS and providing valuable insights for clinical recognition.

#4

Review of Cutaneous Manifestations in Myhre Syndrome With Histopathological Analyses and Genotype-Phenotype Correlation.

American journal of medical genetics. Part C, Seminars in medical genetics2026 Feb 12

Myhre syndrome is a rare multisystem disorder characterized by distinctive facial features, hearing loss, and progressive fibrosis affecting the skin, joints, lungs, and cardiovascular system. It is caused by heterozygous pathogenic variants in the SMAD4 gene. In this review, we detail the cutaneous manifestations observed in two previously reported patients with genetically confirmed Myhre syndrome. While skin biopsies demonstrated pan-dermal thickening of collagen bundles, the immunohistochemical staining patterns were distinct from those seen in other inflammatory sclerosing disorders. Additionally, we conducted a comprehensive literature review of the cutaneous features associated with Myhre syndrome, identifying 175 patients with confirmed SMAD4 pathogenic variants. The most reported cutaneous finding was thickened or stiff skin (76%), followed by keratosis pilaris (22%) and impaired wound healing or abnormal scarring (18%). Genotype-phenotype analysis suggested a diagnostic delay in patients with the codon 496 variant, who were more frequently diagnosed in adulthood. This variant may also be associated with a milder cutaneous phenotype, highlighting the clinical heterogeneity of Myhre syndrome. These findings underscore the importance of recognizing cutaneous features as potential early diagnostic clues in patients with suspected Myhre syndrome.

#5

Unraveling the Mechanistic Spectrum of Myhre Syndrome: SMAD4 Signaling Disruption, Skeletal Phenotypes, and Translational Innovation.

American journal of medical genetics. Part C, Seminars in medical genetics2026 Feb 08

Myhre syndrome (MYHRS) is an ultra-rare, progressive multisystem disorder caused by recurrent heterozygous missense variants in the SMAD4 gene, a central mediator of TGF-β and BMP signaling. Skeletal abnormalities-including postnatal short stature, brachydactyly, thickened calvarium, and craniofacial dysmorphism-are cardinal features, often accompanied by joint contractures and progressive soft tissue fibrosis. Extensive cellular and genetic evidence supports a gain-of-function (GoF) mechanism wherein mutant SMAD4 displays increased protein stability and prolonged nuclear localization, enhancing canonical SMAD signaling and driving overexpression of profibrotic and extracellular matrix (ECM) genes. Although a dominant-negative (DN) effect was recently proposed for some variants, GoF remains the prevailing and best-supported model. The underlying skeletal pathophysiology likely reflects both primary disruption of mesenchymal differentiation affecting bone and cartilage, and secondary progressive fibrosis that amplifies contractures and skeletal rigidity over time, though direct mechanistic studies in bone tissue remain limited. Therapeutically, TGF-β pathway inhibitors such as losartan exhibit promising in vitro and early clinical benefits, while advanced strategies-spanning targeted small molecules, anti-fibrotic agents, and emerging gene-editing approaches-are prospective direction for therapies. The integration of patient-derived iPSC models engineered animal systems, multi-modal technologies, and artificial intelligence (AI) holds significant promise for precision medicine in Myhre syndrome.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC89 artigos no totalmostrando 75

2026

Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents.

American journal of medical genetics. Part C, Seminars in medical genetics
2026

Myhre Syndrome Presenting With Congenital Proximal Radioulnar Synostosis: A Case Report.

Cureus
2026

Review of Cutaneous Manifestations in Myhre Syndrome With Histopathological Analyses and Genotype-Phenotype Correlation.

American journal of medical genetics. Part C, Seminars in medical genetics
2026

Unraveling the Mechanistic Spectrum of Myhre Syndrome: SMAD4 Signaling Disruption, Skeletal Phenotypes, and Translational Innovation.

American journal of medical genetics. Part C, Seminars in medical genetics
2026

A Novel Gain-of-Function ITPR1 Variant Associated With a Movement Disorder Characterized by Tremor and Dystonia.

American journal of medical genetics. Part A
2025

Anesthetic Management of a Patient With Myhre Syndrome.

Anesthesia progress
2025

Autosomal Dominant Transmission Reframes Reproductive Counseling in Myhre Syndrome: A Novel Family and Literature Review.

American journal of medical genetics. Part C, Seminars in medical genetics
2026

A proposed nosology of inherited disorders of the extracellular matrix (ECM): Insights from the IEMbase and dyadic classification.

Molecular genetics and metabolism
2025

Detailed Autopsies Performed on Two Females With Myhre Syndrome Elucidate Features of SMAD4 Gain-of-Function Pathophysiology.

American journal of medical genetics. Part C, Seminars in medical genetics
2025

Evaluation of the Mid and Lower Face in Three Females With Myhre Syndrome: Objective Methods to Supplement Subjective Assessment.

American journal of medical genetics. Part C, Seminars in medical genetics
2025

Descriptive Epidemiology From the Myhre Syndrome Foundation Registry: The Value of Self-Reported Data.

American journal of medical genetics. Part C, Seminars in medical genetics
2025

Navigating Drug Discovery for Myhre Syndrome: The Complexity of a Multisystemic Rare Disease.

American journal of medical genetics. Part C, Seminars in medical genetics
2026

Identification and characterization of a TGF-β-independent SMAD4-NFATc1-STAT3 regulatory axis.

Journal of molecular cell biology
2025

Cardio-Respiratory Complications in Adult Monozygotic Twins With Myhre Syndrome.

American journal of medical genetics. Part C, Seminars in medical genetics
2025

The Diagnosis That Arrived Decades Late: Living Without and Then With Myhre Syndrome.

American journal of medical genetics. Part C, Seminars in medical genetics
2025

Journaling for Parents and Adults With Myhre Syndrome: Using Reflective Writing to Help Cope.

American journal of medical genetics. Part C, Seminars in medical genetics
2025

Foveal hypoplasia in Myhre syndrome: a novel association.

Ophthalmic genetics
2025

Research Review of Myhre Syndrome.

American journal of medical genetics. Part C, Seminars in medical genetics
2025

Myhre syndrome: Endoscopic airway presentation.

International journal of pediatric otorhinolaryngology
2025

2024 VCP International Conference: Exploring multi-disciplinary approaches from basic science of valosin containing protein, an AAA+ ATPase protein, to the therapeutic advancement for VCP-associated multisystem proteinopathy.

Neurobiology of disease
2025

Thick skin and thicker arteries: case report on a rare cause of hypertension.

Pediatric nephrology (Berlin, Germany)
2025

SMAD4 Pathogenic Variants in Seven New Brazilian Individuals With Myhre Syndrome Including a New Family.

American journal of medical genetics. Part A
2024

Spontaneous Coronary Artery Dissection: Current Knowledge, Research Gaps, and Innovative Research Initiatives: JACC Advances Expert Panel.

JACC. Advances
2025

Myhre syndrome: case report.

Medicina clinica
2024

The Myhre Syndrome Foundation as a global modern support group: The business of rare.

American journal of medical genetics. Part C, Seminars in medical genetics
2025

Gain-of-function variants in SMAD4 compromise respiratory epithelial function.

The Journal of allergy and clinical immunology
2024

Prenatal Diagnosis of Myhre Syndrome in Two Cases: Further Delineation of the Cardiac and External Phenotype.

Prenatal diagnosis
2024

SMAD4 mutations causing Myhre syndrome are under positive selection in the male germline.

American journal of human genetics
2024

Myhre syndrome in adulthood: clinical variability and emerging genotype-phenotype correlations.

European journal of human genetics : EJHG
2024

Middle Ear Fibrosis Contributes to Hearing Loss in Patients With Myhre Syndrome.

Ear, nose, &amp; throat journal
2024

Emergence of the natural history of Myhre syndrome: 47 patients evaluated in the Massachusetts General Hospital Myhre Syndrome Clinic (2016-2023).

American journal of medical genetics. Part A
2024

Corrigendum to "Gain-of-function pathogenic variants in SMAD4 are associated with neoplasia in Myhre syndrome".

American journal of medical genetics. Part A
2023

Psychiatric manifestations of Myhre syndrome: A case report.

Indian journal of psychiatry
2023

SMAD4 variants and its genotype-phenotype correlations to juvenile polyposis syndrome.

Hereditary cancer in clinical practice
2023

The Multifaceted Syndromic Primary Immunodeficiencies in Children.

Journal of clinical medicine
2023

Prenatal diagnosis of Myhre syndrome with a heterozygous pathogenic variant in SMAD4 gene presented with thick nuchal translucency and cardiac abnormalities.

Prenatal diagnosis
2023

Myhre syndrome: expanding its paediatric phenotypic spectrum.

Cardiology in the young
2023

A Second Family with Myhre Syndrome Caused by the Same Recurrent SMAD4 Pathogenic Variation (p.Arg496Cys).

Molecular syndromology
2023

A newborn male with Myhre syndrome, hearing loss, and complete syndactyly of fingers 3-4.

Molecular genetics &amp; genomic medicine
2022

Myhre syndrome is caused by dominant-negative dysregulation of SMAD4 and other co-factors.

Differentiation; research in biological diversity
2022

Review of the Pathologic Characteristics in Myhre Syndrome: Gain-of-Function Pathogenic Variants in SMAD4 cause a Multisystem Fibroproliferative Response.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
2022

Natural history of Myhre syndrome.

Orphanet journal of rare diseases
2022

An additional patient with SMAD4-Juvenile Polyposis-Hereditary hemorrhagic telangiectasia and connective tissue abnormalities: SMAD4 loss-of-function and gain-of-function pathogenic variants result in contrasting phenotypes.

American journal of medical genetics. Part A
2022

First documented case of Myhre syndrome in Romania: A case report.

Experimental and therapeutic medicine
2022

Cardiomyopathies in Children and Systemic Disorders When Is It Useful to Look beyond the Heart?

Journal of cardiovascular development and disease
2022

Expanded cardiovascular phenotype of Myhre syndrome includes tetralogy of Fallot suggesting a role for SMAD4 in human neural crest defects.

American journal of medical genetics. Part A
2022

Myhre syndrome associated with hyperinsulinism and impaired glucose tolerance: a novel finding.

Clinical dysmorphology
2021

First case of Myhre syndrome with schizophrenia.

Clinical dysmorphology
2021

Benefit of cochlear implantation in a patient with Myhre syndrome.

BMJ case reports
2021

Case Report: Improved Height in a Patient With Myhre Syndrome Using a Combination of Growth Hormone and Letrozole.

Frontiers in pediatrics
2021

Myhre Syndrome Misdiagnosed as Marfan Syndrome: an Educational Presentation.

Brazilian journal of cardiovascular surgery
2021

Multilevel Airway Stenosis Being Bypassed by a Customized Tracheostomy Tube in an Infant with Myhre Syndrome.

Pediatric allergy, immunology, and pulmonology
2021

Myhre syndrome: the first case in Korea.

Annals of pediatric endocrinology &amp; metabolism
2021

Lack of resemblance between Myhre syndrome and other "segmental progeroid" syndromes warrants restraint in applying this classification.

GeroScience
2021

SMAD4 mutations and cross-talk between TGF-β/IFNγ signaling accelerate rates of DNA damage and cellular senescence, resulting in a segmental progeroid syndrome-the Myhre syndrome.

GeroScience
2021

A pilot clinical trial with losartan in Myhre syndrome.

American journal of medical genetics. Part A
2020

A case of Myhre syndrome mimicking juvenile scleroderma.

Pediatric rheumatology online journal
2020

Myhre Syndrome Associated With Dunbar Syndrome and Urinary Tract Abnormalities: A Case Report.

Frontiers in pediatrics
2020

Novel Ocular and Inner Ear Anomalies in a Patient with Myhre Syndrome.

Molecular syndromology
2020

Gain-of-function pathogenic variants in SMAD4 are associated with neoplasia in Myhre syndrome.

American journal of medical genetics. Part A
2020

The first two Chinese Myhre syndrome patients with the recurrent SMAD4 pathogenic variants: Functional consequences and clinical diversity.

Clinica chimica acta; international journal of clinical chemistry
2019

Myhre syndrome: A first familial recurrence and broadening of the phenotypic spectrum.

American journal of medical genetics. Part A
2020

Life-Threatening Multilevel Airway Stenosis Due to Myhre Syndrome.

American journal of respiratory and critical care medicine
2019

Autism Spectrum Disorder and Psychiatric Comorbidity in a Patient with Myhre Syndrome.

Journal of autism and developmental disorders
2019

Myhre syndrome: a report of six Chinese patients and literature review.

Clinical dysmorphology
2017

Myhre syndrome: Age-dependent progressive phenotype.

Pediatrics international : official journal of the Japan Pediatric Society
2018

A child with Myhre syndrome presenting with corectopia and tetralogy of Fallot.

American journal of medical genetics. Part A
2018

Myhre syndrome with novel findings: bilateral congenital cortical cataract, bilateral papilledema, accessory nipple, and adenoid hypertrophy.

Clinical dysmorphology
2017

Smad4 regulates growth plate matrix production and chondrocyte polarity.

Biology open
2016

Natural history and life-threatening complications in Myhre syndrome and review of the literature.

European journal of pediatrics
2016

Gain-of-function mutations in SMAD4 cause a distinctive repertoire of cardiovascular phenotypes in patients with Myhre syndrome.

American journal of medical genetics. Part A
2016

Mutations in LTBP3 cause acromicric dysplasia and geleophysic dysplasia.

Journal of medical genetics
2016

Severe constipation in a patient with Myhre syndrome: a case report.

Clinical dysmorphology
2015

Myhre syndrome: Clinical features and restrictive cardiopulmonary complications.

American journal of medical genetics. Part A
2015

Tumor-suppressor Genes, Cell Cycle Regulatory Checkpoints, and the Skin.

North American journal of medical sciences
Ver todos os 89 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome Myhre.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome Myhre

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Identification and characterization of a TGF-&#x3b2;-independent SMAD4-NFATc1-STAT3 regulatory axis.
    Journal of molecular cell biology· 2026· PMID 40856537mais citado
  2. Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents.
    American journal of medical genetics. Part C, Seminars in medical genetics· 2026· PMID 41834694mais citado
  3. Myhre Syndrome Presenting With Congenital Proximal Radioulnar Synostosis: A Case Report.
    Cureus· 2026· PMID 41769593mais citado
  4. Review of Cutaneous Manifestations in Myhre Syndrome With Histopathological Analyses and Genotype-Phenotype Correlation.
    American journal of medical genetics. Part C, Seminars in medical genetics· 2026· PMID 41680107mais citado
  5. Unraveling the Mechanistic Spectrum of Myhre Syndrome: SMAD4 Signaling Disruption, Skeletal Phenotypes, and Translational Innovation.
    American journal of medical genetics. Part C, Seminars in medical genetics· 2026· PMID 41656577mais citado
  6. Spectrum of Congenital Anomalies in Myhre Syndrome-Insights Into Effects Brought by Altered TGF-β Signaling via Gain-of-Function Variants in SMAD4.
    Am J Med Genet C Semin Med Genet· 2026· PMID 41968855recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:2588(Orphanet)
  2. OMIM OMIM:139210(OMIM)
  3. MONDO:0007688(MONDO)
  4. GARD:2572(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q17042115(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Síndrome Myhre

ORPHA:2588 · MONDO:0007688
Prevalência
<1 / 1 000 000
Herança
Autosomal dominant
CID-10
Q87.8 · Outras síndromes com malformações congênitas especificadas, não classificadas em outra parte
Ensaios
1 ativos
Início
Antenatal, Infancy, Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0796081
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades